GRI Bio Regains Compliance With Nasdaq
GRI Bio Regains Compliance With Nasdaq
LA JOLLA, CA, July 08, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it received notice on July 2, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") that the Company regained compliance with all applicable Nasdaq listing standards for continued listing on the Nasdaq Capital Market, and that the scheduled hearing before the Hearings Panel has been canceled.
生物技术公司GRI Bio, Inc.(纳斯达克股票代码:GRI)(“GRI Bio”或“公司”)正在推进创新的天然杀伤性t(NKT)细胞调节剂产品线,用于治疗炎症、纤维化和自身免疫性疾病。2024年7月2日,纳斯达克证券市场有限责任公司(“纳斯达克”)向GRI Bio通知公司已恢复符合纳斯达克资格上市标准,并取消了关于听证会的安排。
"We are very excited about this development and look forward to focusing our efforts on our core business-developing novel product candidates for the treatment of inflammatory, fibrotic and autoimmune diseases," said Marc Hertz, GRI Bio's Chief Executive Officer."
“我们对此发展非常兴奋,并期待将我们的精力集中于我们的核心业务 - 开发新型产品治疗炎症、纤维化和自身免疫性疾病,” GRI Bio首席执行官Marc Hertz说。
About GRI Bio, Inc.
关于GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of Natural Killer T ("NKT") cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT ("iNKT") cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
GRI Bio是一家专注于根本性改变炎症、纤维化和自身免疫性疾病治疗方式的临床阶段生物制药公司。GRI Bio的产品旨在针对自然杀伤T(“NKT”)细胞的活性,这些细胞是炎症级联早期的关键调节因子,以打断疾病进展和恢复免疫系统的稳态。NKT细胞是具有NK和T细胞性质的先天样T细胞,是先天和适应性免疫反应之间的功能性链接。I型不变NKT(“iNKT”)细胞在炎症和纤维化症状中发挥关键作用。 GRI Bio的主导项目GRI-0621是iNKT细胞活性抑制剂,正在开发作为治疗特发性肺纤维化的新型口服药物,这是一种有重大未满足需求的严重疾病。该公司还正在开发一系列新型2型NKT激动剂,用于治疗系统性红斑狼疮。此外,GRI Bio拥有超过500种专有化合物的库,可为其不断壮大的管道提供动力。
Forward-Looking Statements
前瞻性声明
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions. These forward-looking statements are based on the Company's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the Company's expectations with respect to development and commercialization of the Company's product candidates, the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company's clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials, and the Company's continued compliance with applicable Nasdaq listing standards. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company's common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company's product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company's products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) the failure to achieve any milestones or receive any milestone payments under any agreements; (10) inaccuracy in the Company's estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (11) the Company's ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (12) other risks and uncertainties indicated from time to time in the Company's filings with the U.S. Securities and Exchange Commission (the "SEC"), including the risks and uncertainties described in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K filed with the SEC on March 28, 2024 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
本新闻稿包含“前瞻性声明”,这些声明在《1995年私有证券诉讼改革法》的“安全港”规定下。前瞻性声明可能通过使用诸如“预计”、“相信”、“思考”、“可能”、“估计”、“期望”、“打算”、“寻求”、“未来”、“或者其他类似表述的字眼来识别。这些前瞻性声明基于公司当前的信念和期望。前瞻性声明包括但不限于关于:本公司产品候选品的开发和商业化的期望、临床试验启动或完成的时间以及所得数据的可用性、本公司临床试验和产品候选品的潜在益处和影响以及任何蕴含在临床前试验或早期研究或试验中观察到的数据或结果可以指示后续研究或临床试验的结果的任何暗示,以及本公司继续遵守适用的纳斯达克上市标准的说明。本新闻稿中的公司的前瞻性声明与实际结果可能有所不同,因此不应将这些前瞻性声明作为对未来事件的预测。这些前瞻性声明受到固有的不确定性、风险和假设的影响,这些不确定性、风险和假设难以预测,包括但不限于:(1)无法在纳斯达克上维护公司普通股的上市地位,并遵守适用的上市要求;(2)适用法律或法规的变化;(3)本公司未来无法筹集资金;(4)本公司的产品开发活动的成功、成本和时间;(5)本公司无法获得和维持对各自产品的监管审批或批准,并且争取到的任何监管批准所伴随的任何限制和限制;(6)本公司无法确定、获得或收购额外技术;(7)本公司无法与目前正在市场上营销或开发公司的产品和服务竞争;(8)本公司的产品和服务所服务的市场的规模和增长潜力,以及它们各自单独或与其他人合作服务这些市场的能力;(9)未能在任何协议项下实现任何里程碑或接收任何里程碑付款;(10)在估计费用、未来营收、资本需求和获得和能力获得额外融资方面的准确性;(11)本公司保护和执行其知识产权组合的能力,包括任何新颁发的专利;以及(12)美国证券交易委员会(“SEC”)从时间到时间在公司提交的文件中指示的其他风险和不确定性,包括在2024年3月28日提交的公司最新年报表单10-k的“风险因素”部分和随后提交的报告中描述的风险和不确定性。本公告中的前瞻性声明是截至本日期作出的,并且除适用法律要求外,公司无需更新此类信息。
Investor Contact:
投资者联系人:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
JTC团队有限责任公司
Jenene Thomas
(833) 475-8247
GRI@jtcir.com